TEM changes
Pick any two versions below to diff them.
- Price
- $71.60 → $54.04(−24.5%)
- Discount category
- Far above intrinsic value → Close to intrinsic value
- Recent events
- Nov added: 18, 2026: Tempus AI and AstraZeneca extended their services agreement through 31 December 2031 on 16 November 2026. AstraZeneca committed $200 million in fees over the five years, with at least $32 million each year. The new term starts on 1 January 2027. Nov 2, 2026: Tempus reported Q3 2026 results. Revenue rose 23% to $411.5 million, Diagnostics revenue rose 20% and Data and Applications revenue rose 33%. The net loss was $14.9 million and adjusted EBITDA was $25.6 million. It raised its 2026 revenue guidance to $1.60 billion to $1.605 billion. It also said that a collaboration with BMS in October brought its data licensing bookings to more than $550 million in 2026. Jul 30, 2026: Tempus reported Q2 2026 results. Revenue rose 22% to $382.5 million, GAAP net income was $5.6 million and adjusted EBITDA was $8.0 million. The FDA approved its xT Tumor Only test. Jul 20, 2026: Tempus agreed to buy the shares of Personalis that it does not already own for $16.25 per share, mostly in Class A shares, an enterprise value of $1.5 billion. Personalis can end the agreement if the average price of Tempus shares before the closing is below $46.00. May 12, 2026: Tempus sold $460.0 million of 0.00% Convertible Senior Notes due 2032, with a conversion price of about $69.26, for net proceeds of $442.0 million. May 5, 2026: Tempus reported Q1 2026 results with revenue of $348.1 million and a net loss of $125.9 million. Feb 24, 2026: Tempus reported 2025 results. Revenue rose 83.4% to $1,271.8 million, the net loss was $245.0 million and the adjusted EBITDA loss was $7.4 million. It guided 2026 revenue of $1.59 billion and adjusted EBITDA of about $65 million.